Related Experiment Video
Updated: Oct 23, 2025

A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research
Published on: August 15, 2019
Research progress of opioid growth factor in immune-related diseases and cancer diseases
1Department of Bone Oncology, The People's Hospital of Liaoning Province, Shenyang, Liaoning Province 110016, China.
Abstract:
Methionine enkephalin (MENK) has an important role in both neuroendocrine and immune systems. MENK was known as an opioid growth factor (OGF) for its growth regulatory characteristics. OGF interacts with the OGF receptor (OGFr) to inhibit DNA synthesis by upregulating p16 and/or p21, which delays the cell cycle transition from G0/G1 to S phase, and inhibits cell proliferation. In addition, OGF combines with OGFr in immune cells to exert its immunomodulatory activity and regulate immune function. OGF has been studied as an immunomodulator in a variety of autoimmune diseases, including multiple sclerosis, inflammatory bowel disease, diabetes and viral infections, and has been proven to relieve symptoms of certain diseases in animal and in vitro experiments. Also, OGF and OGFr have various anti-tumor molecular mechanisms. OGF can be used as the primary therapy alone or combined with other drugs to treat tumors. This article summarizes the research progress of OGF in immune-related diseases and cancer diseases.
Insights
Methionine enkephalin (MENK), also known as opioid growth factor (OGF), regulates cell growth and immune function. Research shows OGF and its receptor (OGFr) hold promise for treating autoimmune diseases and cancers.
Area of Science:
- Neuroendocrinology
- Immunology
- Oncology
Background:
- Methionine enkephalin (MENK) functions as an opioid growth factor (OGF) with critical roles in neuroendocrine and immune systems.
- OGF, through interaction with its receptor (OGFr), inhibits DNA synthesis and cell proliferation by upregulating cell cycle inhibitors p16 and/or p21.
- OGF/OGFr signaling modulates immune cell function and has been investigated for autoimmune diseases and viral infections.
Purpose of the Study:
- To summarize research progress on the therapeutic potential of OGF in immune-related diseases and cancer.
- To highlight the molecular mechanisms underlying OGF's effects in these conditions.
Main Methods:
- Literature review of studies on OGF/OGFr in autoimmune diseases and cancer.
- Analysis of experimental data from in vitro and animal models.
- Examination of molecular pathways involved in OGF's action.
Main Results:
- OGF/OGFr signaling demonstrates immunomodulatory effects, showing symptom relief in autoimmune disease models.
- OGF exhibits anti-tumor properties through various molecular mechanisms.
- Preclinical studies suggest OGF's potential as a monotherapy or adjunct treatment for tumors.
Conclusions:
- OGF and OGFr are significant therapeutic targets for immune-related diseases.
- OGF presents a promising therapeutic strategy for cancer treatment.
- Further research into OGF/OGFr pathways could lead to novel treatments for complex diseases.
More Related Videos
Related Concept Videos
Mitogens and the Cell Cycle
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...
Opioid Receptors: Overview
Analgesia and Pain Management
Role of Hematopoietic Growth Factors
Thrombopoietin (TPO), mainly released by the liver,...
Opioid Analgesics: Morphine and Other Natural Cogeners

